Create Account | Sign In: Author or Forum

 
 
News  |  Journals  |  Conferences  |  Blogs  |  Articles  |  Forums  |  Twitter    
 

 Headlines:

 

Category: Family Medicine | Neurology | Nursing | Pediatrics | Pharmacy | Journal

Back to Journal Articles

Life-Long Rx Not Always Needed for Juvenile Myoclonic Epilepsy

Last Updated: June 13, 2012.

 

JME is heterogeneous syndrome; life-long treatment not always needed to maintain seizure freedom

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
Juvenile myoclonic epilepsy is a heterogeneous epilepsy syndrome and life-long antiepileptic drug treatment is not required in all patients to maintain seizure freedom, according to a study published online June 12 in Epilepsia.

WEDNESDAY, June 13 (HealthDay News) -- Juvenile myoclonic epilepsy (JME) is a heterogeneous epilepsy syndrome and life-long antiepileptic drug (AED) treatment is not required in all patients to maintain seizure freedom, according to a study published online June 12 in Epilepsia.

To investigate the long-term seizure outcome and predictors of seizure outcome, Julia Geithner, from the University of Greifswald in Germany, and colleagues analyzed long-term follow up data (mean, 39.1 years) from 31 patients (19 women) diagnosed with JME. The participants were reassessed through a review of medical records and direct interviews.

The researchers found that two-thirds of patients (67.7 percent) became seizure free, and AED treatment was discontinued due to seizure freedom in six patients (28.6 percent). Significant predictors for a poor long-term seizure outcome included the occurrence of generalized tonic-clonic seizures (GTCS) preceded by bilateral myoclonic seizures (BMS), a long duration of unsuccessful treatment, and AED polytherapy. The chance for complete freedom from seizures increased significantly with complete remission of GTCS under AED. The risk of seizure recurrence after AED discontinuation was significantly increased with the occurrence of photoparoxysmal responses.

"Our study shows that JME is likely a heterogeneous epilepsy syndrome," the authors write. "Our findings of long-term seizure freedom and the statistical validation of several outcome predictors can potentially increase the clinicians' ability and confidence to recommend different treatment options to patients with JME."

Abstract
Full Text (subscription or payment may be required)

Copyright © 2012 HealthDay. All rights reserved.


Previous: Task Force Questions Use of Vitamin D, Calcium Supplements Next: SLEEP: CPAP Ups Sexual Function for Men With Sleep Apnea

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

  • Ask a Doctor Teams: Respond to patient questions and discuss challenging presentations with other members.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2013
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.